Plain-English translation of NCT05978193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining radiation therapy with a PD-1 inhibitor (an medication), along with , works better than and alone for people with metastatic esophageal squamous cell carcinoma — a type of esophageal cancer that has spread to other parts of the body. The study first tests whether this new combination is safe, then compares it to the standard treatment to see if it helps patients live longer without their cancer growing.
Current treatments for advanced esophageal cancer have limited effectiveness, and doctors often give radiation therapy mainly to help with swallowing difficulties. Recent research suggests that combining radiation with might work better together than either treatment alone, so this trial is designed to find out whether adding this medication can improve survival.
You likely qualify if…
You likely don't qualify if…
First, about 20–25 patients will receive the experimental combination (radiation plus the medication and ) to make sure it is safe. If it appears safe enough, the trial will then randomly assign new participants into two groups: one receiving the full combination treatment, and another receiving the medication and without radiation. Participants will receive treatment over several months and have regular visits to monitor their progress, side effects, and how their cancer is responding.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China